Published in:
01-09-2020 | Photodynamic Therapy | Retinal Disorders
Long-term results of choroidal neovascularization secondary to angioid streaks
Authors:
Hidetsugu Mori, Haruhiko Yamada, Kanji Takahashi
Published in:
Graefe's Archive for Clinical and Experimental Ophthalmology
|
Issue 9/2020
Login to get access
Abstract
Purpose
To investigate factors contributing to the visual prognosis of choroidal neovascularization (CNV) secondary to angioid streaks (AS) in a long-term follow-up (> 5 years) study.
Methods
Twenty-one patients (32 eyes) affected by CNV secondary to AS were enrolled retrospectively and divided into three groups according to the period of CNV recurrence from the final treatment: group A, no recurrence for more than 12 months; group B, no recurrence for 6–12 months; and group C, no recurrence for < 6 months or ongoing. According to the above classification, we assessed best-corrected visual acuity (BCVA), peau d’orange area, the number of photodynamic treatments and/or intravitreal antiangiogenic drug injections, central choroidal thickness (CCT) and central retinal thickness (CRT) using optical coherence tomography, and enlargement of retinal pigment epithelium (RPE) atrophy.
Results
The median follow-up time was 91 months. The median logarithm of the minimum angle of resolution BCVA significantly deteriorated from 0 at baseline to 1 at final follow-up (p < 0.05). Especially, final BCVA in group A showed worst visual outcome despite lowest number of treatments. Peau d’orange areas at baseline were found in 32 eyes (100%). There were no significant differences between initial CRT and final CRT. Median CCT was significantly reduced from 188 μm at baseline to 96 μm at final follow-up (p < 0.05). The median number of treatments was 3.5. Enlargement of RPE atrophy at baseline was found in 31 eyes (96.8%).
Conclusions
Despite the regression of CNV secondary to AS following treatment, the visual prognosis was poor due to the presence of peau d’orange areas, choroidal thinning, and increased RPE atrophy.